With an overall frequency of 60%, p53 mutations are highly relevant in breast cancer (BC) [5] and the prevalence of p53 mutations is about 20% in primary luminal (i.e., estrogen receptor-positive, ESR) BC, 70% in triple negative, and 40% in HER2-enriched BC [6]. Here, ERBB2 is linked to breast cancer.